Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chimonanthus nitens Oliv. leaf extract (COE) is a botanical extract derived from the leaves of *Chimonanthus nitens* Oliv., a plant in the Calycanthaceae family traditionally used for herbal tea in southern China. The extract is typically prepared using ethanol and contains bioactive compounds such as flavonoids (quercetin, kaempferol), coumarins, and phenolic acids. Preclinical research indicates that COE may alleviate hyperlipidemia by activating the leptin/JAK2/STAT3 signaling pathway, which leads to the upregulation of CYP7A1 and downregulation of HMGCR in the liver. Additionally, the extract exhibits anti-diabetic properties through alpha-glucosidase inhibition and anti-inflammatory effects by modulating cytokines like TNF-alpha and IL-6. While studied in various animal models, there is currently no evidence of formal pharmaceutical development or clinical trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chimonanthus nitens Oliv. leaf extract.